Uropathogenic E. coli is one of the major agents of urinary tract infection. Today, no effective treatment or vaccine against this infection is exist. Accordingly, in the present study, a genetic constrruct for inducing of cellular immune system was designed. At first, fimH gene from E. coli 35218 was amplified using PCR. PCR product inserted into pET23a expression vector and the recombinant vector was analysed by sequencing. The vector was transformed to E. coli strain Origami and the protein was expressed under the 1 mM IPTG. FimH was purified with Ni-NTA column and the purified protein was used for immunization of BALB/c. Two weeks after the last injection, lymphocyte proliferation assay was carried out. In addition, IL-4 and IFN- cytokines, total antibody serum, IgG1 and IgG2a isotypes were quantified. Finally, protection ability of the vaccine in bladder and kidney infection of mice was evaluated.
The results indicated that cellular immune response has a main protective role against UTI and FimH, as a vaccine candidate, significantly increase lymphocyte proliferation, IFN- response and total antibody amount. Immunization of mice with FimH conferred effective protection of kidney and bladder against urinary tract infection by uropathogenic E. coli ( 0.002). It can be concluded that, the current FimH will be valuable for more trying to prepare a new vaccine against UTI.
Flores-MirelesA.L.WalkerJ.N.CaparonM. and HultgrenS.J., Urinary tract infections: Epidemiology, mechanisms of infection and treatment options, Nat Rev Microbiol13 (2015), 269–284.
2.
MicaliS.IsgroG.BianchiG.MiceliN.CalapaiG. and NavarraM., Cranberry and recurrent cystitis: More than marketing? Crit Rev Food Sci Nutr54 (2014), 1063–1075.
3.
FoxmanB., Urinary tract infection syndromes occurrence, recurrence, bacteriology, risk factors, and disease burden, Infect Dis Clin North Am28 (2014), 1–13.
4.
RussoT.A.StapletonA.WenderothS.HootonT.M. and StammW.E., Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women, J Infect Dis172 (1995), 440–445.
5.
WuX.R.KongX.P.PellicerA.KreibichG. and SunT.T., Uroplakins in urothelial biology, function, and disease, Kidney Int75 (2009), 1153–1165.
6.
GristM. and ChakrabortyJ., Identification of a mucin layer in the urinary bladder, Urology44 (1994), 26–33.
7.
FoxmanB.BarlowR.D’ArcyH.GillespieB. and SobelJ.D., Urinary tract infection: Self-reported incidence and associated costs, Ann Epidemiol10 (2000), 509–515.
8.
SchaefferA.J., Recurrent urinary tract infections in women. Pathogenesis and management, Postgrad Med81 (1987), 51–58.
9.
GuptaK.HootonT.M. and StammW.E., Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections, Ann Intern Med135 (2001), 41–50.
10.
BrumbaughA.R.SmithS.N. and MobleyH.L., Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection, Infect Immun81 (2013), 3309–3316.
11.
WeyrauchH.M.RosenbergM.L.AmarA.D. and RedorM., Effects of antibiotics and vaccination on experimental pyelonephritis, J Urol78 (1957), 532–539.
12.
HagbergL.EngbergI.FreterR.LamJ.OllingS. and EdenC.S., Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin, Infect Immun40 (1983), 273–283.
13.
MartinezJ.J.MulveyM.A.SchillingJ.D.PinknerJ.S. and HultgrenS.J., Type 1 pilusmediated bacterial invasion of bladder epithelial cells, EMBO J19 (2000), 2803–2812.
14.
WrightK.J.SeedP.C. and HultgrenS.J., Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili, Cell Microbiol9 (2007), 2230–2241.
15.
ThankavelK.MadisonB.IkedaT.MalaviyaR.ShahA.H. and ArumugamP.M. et al., Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection, J Clin Invest100 (1997), 1123–1136.
16.
ConnellI.AgaceW.KlemmP.SchembriM.MarildS. and SvanborgC., Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract, Proc Natl Acad Sci U.S. A93 (1996), 9827–9832.
17.
HanleyO’P.LarkD.FalkowS.SchoolnikG., Molecular basis of Escherichia coli colonization of the upper urinary tract in BALB/c mice. Gal-Gal pili immunization prevents Escherichia coli pyelonephritis in the BALB/c mouse model of human pyelonephritis, J Clin Invest75 (1985), 347–360.
18.
LangermannS.MollbyR.BurleinJ.E.PalaszynskiS.R.AugusteC.G.DeFuscoA.StrouseR.SchenermanM.A.HultgrenS.J.PinknerJ.S.WinbergJ.GuldevallL.SoderhallM.IshikawaK.NormarkS. and KoenigS., Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli, J Infect Dis181 (2000), 774–778.
19.
JohnsonD.E.RussellR.G.LockatellC.V.ZultyJ.C.WarrenJ.W. and MobleyH.L., Contribution of Proteus mirabilis urease to persistence, urolithiasis, and acute pyelonephritis in a mouse model of ascending urinary tract infection, Infect Immun61 (1993), 2748–2754.
20.
MehrabadiJ.F.NejadQ.B.PeerayehS.N.KhodabandehM.SoleimanjahiH. and HassanA.M., Construcion of pCDNA/fimH cassette as a DNA vaccine candidate against urinary tract infection and evaluation of fimH transcription in Cos-7 cell line, Research Journal of Microbiology4 (2009), 75–81.
21.
JonesC.H.PinknerJ.S.RothR.HeuserJ.NicholesA.V.AbrahamS.N. and HultgrenS.J., FimH adhesin of type 1 pili is assembled into a ¢brillar tip structure in the Enterobacteriaceae, Proc Natl Acad Sci USA92 (1995), 2081–2085.
22.
KnudsenT.B. and KlemmP., Probing the receptor binding site of the FimH adhesin by Fimbriae-displayed FimH-FocH hybrids, Microbiology144 (1998), 1919–1929.
23.
PetschD. and AnspachF.B., Endotoxin removal from protein solutions, J Biotechnol76 (2000), 97–119.
ChenQ.HeF.KwangJ.ChanJ.K. and ChenJ., GM-CSF and IL-4 stimulate antibody responses in humanized mice by promoting T, B, and dendritic cell maturation, J Immunol189 (2012), 5223–5229.
26.
HarkerJ.A.LewisG.M.MackL. and ZunigaE.I., Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection, Science334 (2011), 825–829.
27.
Asadi KaramM.R.OloomiM.MahdaviM.HabibiM. and BouzariS., Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice, Vaccine31(8) (2013), 1210–1216.
28.
RothwellL.YoungJ.R.ZoorobR.WhittakerC.A.HeskethP.ArcherA.SmithA.L. and KaiserP., Cloning and characterization of chicken IL-10 and its role in the immune response to Eimeria maxima, J Immunol173 (2004), 2675–2682.
29.
GazzinelliR.T.OswaldI.P.JamesS.L. and SherA., IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages, J Immunol148 (1992), 1792–1796.
30.
LiX.LockatellC.V.JohnsonD.E.LaneM.C. and WarrenJ.W., Mobley HLDevelopment of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis, Infect Immun72(1) (2004), 66–75.
31.
LangermannS.PalaszynskiS.BarnhartM.AugusteG.PinknerJ.S.BurleinJ.BarrenP.KoenigS.LeathS.JonesC.H. and HultgrenS.J., Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination, Science276 (1997), 607–611.
LangermannS. and BallouW.R., Vaccination utilizing the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections, J Infect Dis183 (2001), S84–S86.
